Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Latosha Corley

Nurse Practitioner, Gerontology Orangeburg, SC Nurse Practitioner

NPI 1376193383 CMS profile 11218989

3000 Saint Matthews Rd, Orangeburg, SC 29118

Open in the dashboard

General payments

$1,628

99 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Latosha Corley of Orangeburg, SC is reported in the CMS Open Payments database as having received $1,628 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $433 36
2022 General $499 28
2021 General $697 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Latosha Corley
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Latosha Corley were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Latosha Corley Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $697 $133 $44–$396 $132
2022 $499 $142 $48–$452 $149
2023 $433 $158 $53–$482 $160
2024 $0 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Janssen Pharmaceuticals, Inc $240 13 payments
  2. AstraZeneca Pharmaceuticals LP $218 8 payments
  3. Lilly USA, LLC $207 11 payments
  4. AbbVie, Inc. $142 21 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $94 4 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $92 4 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $78 5 payments
  8. Arbor Pharmaceuticals, Inc. $68 4 payments
  9. Sanofi-Aventis U.S. LLC $60 4 payments
  10. Novo Nordisk Inc $53 4 payments
  11. Other $375 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $1,628 99 payments
Products named General payments · program years 2021–2023
  1. XARELTO $240 13 payments
  2. BREZTRI $173 5 payments
  3. VRAYLAR $142 21 payments
  4. XIFAXAN $120 8 payments
  5. MOUNJARO $117 6 payments
  6. Kerendia $94 4 payments
  7. JARDIANCE Diabetes $92 4 payments
  8. JARDIANCE Diabetes $74 4 payments
  9. SOLIQUA 100/33 $60 4 payments
  10. RYBELSUS $53 4 payments
  11. Other $760 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

4,654

Median for Nurse Practitioner: 389

Drug cost

$460,403

Median for Nurse Practitioner: $21,885

Branded share of claims

21.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 111 $127,497
Eliquis Apixaban Brand 47 $44,996
Trulicity Dulaglutide Brand 29 $31,543
Kerendia Finerenone Brand 32 $26,637
Ozempic Semaglutide Brand 26 $26,197
Farxiga Dapagliflozin Propanediol Brand 18 $22,294
Jardiance Empagliflozin Brand 22 $22,289
Xarelto Rivaroxaban Brand 11 $14,329
Entresto Sacubitril/Valsartan Brand 16 $14,186
Januvia Sitagliptin Phosphate Brand 23 $13,947

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$18,119

Of which drugs: $867

Medicare patients

131

Average age 75

Services billed

660

99 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 47%
Ischemic heart disease 21%
Chronic kidney disease 20%
Depression 15%
Cancer 12%
Osteoporosis 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record